This inventor holds 1 USPTO granted patent. Top assignee: Laboratories Negma. Active years: 1988.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1988
Title: Nicole Monfilliette: Innovator in Pharmaceutical Chemistry
Introduction
Nicole Monfilliette is a prominent inventor based in Villeneuve-d'Ascq, France. She has made significant contributions to the field of pharmaceutical chemistry, particularly through her innovative work on benzoxazinones. Her research focuses on the development of new medicaments that can improve health outcomes.
Latest Patents
Nicole holds a patent for the "Use of 7-acyl benzoxazinones and their derivatives in treating." This invention relates to products characterized by a specific general formula, where R1, R2, R3, R, and X have defined meanings as indicated in her patent claims. The invention also encompasses pharmaceutical compositions that can be administered orally, containing these compounds in association with a pharmaceutically acceptable vehicle. These compounds are recognized for their potential utility as medicaments.
Career Highlights
Nicole Monfilliette is associated with Laboratories Negma, where she has been instrumental in advancing pharmaceutical research. Her work has led to the development of innovative treatments that address various health issues. With her expertise, she has contributed to the growth of the company and the pharmaceutical industry as a whole.
Collaborations
Nicole has collaborated with notable colleagues, including Charles Lespagnol and Jean-Claude Fruchart. These partnerships have fostered a collaborative environment that enhances research and development efforts within the company.
Conclusion
Nicole Monfilliette's contributions to pharmaceutical chemistry exemplify the impact of innovation in healthcare. Her patent and collaborative efforts highlight her commitment to advancing medical science. Through her work, she continues to pave the way for new therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile